Patient perspectives on considerations, tradeoffs, and experiences with multiple myeloma treatment selection: a qualitative descriptive study

BMC Cancer

Research

David Chandler¹  Carrie Dombeck²  Teresa Swezey²  Thomas W. LeBlanc³  Amy Corneli⁴  Juan Marcos Gonzalez Sepulveda⁴  Bryce B. Reeve⁵ 

[1] Amgen, Inc, Thousand Oaks, CA, USA;Department of Population Health Sciences, Duke University School of Medicine, 215 Morris Street, 27701, Durham, NC, USA;Department of Population Health Sciences, Duke University School of Medicine, 215 Morris Street, 27701, Durham, NC, USA;Department of Medicine, Duke University School of Medicine, Durham, NC, USA;Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA;Department of Population Health Sciences, Duke University School of Medicine, 215 Morris Street, 27701, Durham, NC, USA;Department of Medicine, Duke University School of Medicine, Durham, NC, USA;Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA;Department of Population Health Sciences, Duke University School of Medicine, 215 Morris Street, 27701, Durham, NC, USA;Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA;Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA;

关键词: Multiple myeloma;    Treatment selection;    Tradeoffs;    HRQoL;    Qualitative research;    Patients;   

DOI  :  10.1186/s12885-022-10458-x

 received in 2022-08-16, accepted in 2022-12-19,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundAdvances in multiple myeloma treatment and a proliferation of treatment options have resulted in improved survival rates and periods of symptom-free remission for many multiple myeloma patients. As a result, health-related quality of life (HRQoL) concerns related to myeloma treatments have become increasingly salient for this patient population and represent an important consideration guiding patients’ treatment choices. To gain an understanding of patients’ experiences with choosing myeloma therapies and explore the HRQoL concerns that are most important to them, we interviewed a diverse sample of US-based multiple myeloma patients about their treatment considerations.MethodsWe conducted a qualitative descriptive study using in-depth interviews. Participants reflected on (1) the factors that were most important to them when thinking about multiple myeloma treatment and how these have changed over time, (2) how they might weigh the importance of treatment efficacy vs. side effects, (3) trade-offs they would be willing to make regarding efficacy vs. HRQoL, and (4) treatment changes they had experienced. Interviews were audio-recorded and transcribed, and narratives were analyzed using applied thematic analysis.ResultsWe interviewed 21 patients, heterogeneous in their disease trajectory and treatment experience. Participants were 36 to 78 years, 52% female, and 38% Black. Efficacy was named as the most important treatment consideration by almost two-thirds of participants, and over half also valued HRQoL aspects such as the ability to maintain daily functioning and enjoyment of life. Participants expressed concern about potential treatment side effects and preferred more convenient treatment options. Although participants stated largely trusting their clinicians’ treatment recommendations, many said they would stop a clinician-recommended treatment if it negatively impacted their HRQoL. Participants also said that while they prioritized treatment efficacy, they would be willing to change to a less efficacious treatment if side effects became intolerable.ConclusionsOur findings link to other reports reflecting considerations that are important to multiple myeloma patients, including the importance placed on increasing life expectancy and progression-free survival, but also the tension between treatment efficacy and quality of life. Our results extend these findings to a racially diverse US-based patient population at different stages in the disease trajectory.

【 授权许可】

CC BY   
© The Author(s) 2023